Lung cancer
Confirm Trial | 2021 | Lung - Mesothelioma |
CHECKMATE 743 trial, ipi/nivo for mesothelioma | 2021 | Lung - Mesothelioma |
Impower 133 | 2018 | Lung - SCLC |
CASPIAN | 2021 | Lung - SCLC |
PROFILE 1014 trial, crizot vs chemo | 2014 | Lung NSCLC - ALK |
ASCEND-4 trial, cerit vs chemo | 2017 | Lung NSCLC - ALK |
Alex trial, alect vs crizo | 2017 | Lung NSCLC - ALK |
ALTA-1L , briga vs crizo | 2018 | Lung NSCLC - ALK |
Crown trial, lorla vs crizo | 2020 | Lung NSCLC - ALK |
FLAURA trial | 2018 | Lung NSCLC - EGFR |
ADAURA trial, adjuvant Osimertinib | 2020 | Lung NSCLC - EGFR |
Docetaxel in second line | 2000 | Lung NSCLC - advanced |
Confirm Trial
Fennell DA et al, Lancet Onc, 2021, PMID: 34656227
Lung - Mesothelioma
Background. Phase 3 RCT included 332 patients who have previously been treated with two prior lines of chemotherapy in 2:1 ratio
Arm A: Nivolumab 240 mg every 2 weeks
Arm B: Placebo
Primary Endpoint: PFS, OS
Median follow up: 5.09 mo
mPFS: 3.0 mo vs 1.8 mo, arm a vs b respectively, HR 0.67, 95% CI 0.53–0.85, P=.0012
mOS: 10.2 mo vs 6.9 mo, HR 0.69, 95% CI 0.52–0.91, P=.0090
Adverse events. Serious adverse events occurred in 41% vs 44%, including dyspnoea (8% vs 9%), pneumonia (6% vs 5%) and lower respiratory tract infection (4% vs 7%).
Conclusions. Nivolumab improved PFS and OS when compared to placebo amongst patients with malignant pleural or peritoneal mesothelioma previously treated with two prior lines of chemotherapy.
Summarized by Pragnan Kancharla, MD